Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Releases

267 Press Releases
DateTitleCompany
12 Sep 17 Shire Receives FDA Fast Track Designation for SHP607 for the Prevention of Chronic Lung Disease in Extremely Premature Infants Shire plc,
Published by
GlobeNewswire
12 Sep 17 Shire's Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces HAE Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal Trial Shire plc,
Published by
GlobeNewswire
12 Sep 17 Shire's Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces HAE Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal Trial Shire plc,
Published by
GlobeNewswire
12 Sep 17 Shire's Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces HAE Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal Trial Shire plc,
Published by
GlobeNewswire
12 Sep 17 Shire's Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces HAE Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal Trial Shire plc,
Published by
GlobeNewswire
12 Sep 17 Shire's Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces HAE Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal Trial Shire plc,
Published by
GlobeNewswire
12 Sep 17 Shire's Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces HAE Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal Trial Shire plc,
Published by
GlobeNewswire
11 Sep 17 Shire's Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces HAE Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal Trial Shire plc,
Published by
GlobeNewswire
11 Sep 17 Shire's Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces HAE Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal Trial Shire plc,
Published by
GlobeNewswire
11 Sep 17 Shire's Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces HAE Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal Trial Shire plc,
Published by
GlobeNewswire
11 Sep 17 Shire's Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces HAE Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal Trial Shire plc,
Published by
GlobeNewswire
11 Sep 17 Shire's Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces HAE Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal Trial Shire plc,
Published by
GlobeNewswire
11 Sep 17 Shire's Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces HAE Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal Trial Shire plc,
Published by
GlobeNewswire
11 Sep 17 Shire plc : Elections for the interim dividend in respect of the six months to June 30, 2017 Shire plc,
Published by
GlobeNewswire
25 Aug 17 Shire Announces Collaboration with MicroHealth to Address Unique Needs of Hemophilia A and B Patients with Inhibitors Shire ,
Published by
PharmiWeb.com
25 Aug 17 Shire plc : Shire Announces Collaboration with MicroHealth to Address Unique Needs of Hemophilia A and B Patients with Inhibitors Shire plc,
Published by
GlobeNewswire
21 Aug 17 Shire plc Director and Senior Management Changes Shire plc,
Published by
GlobeNewswire
09 Aug 17 Shire plc : Director/PDMR Shareholding Shire plc,
Published by
GlobeNewswire
18 Jul 17 Shire Expands Broad Monoclonal Antibody Research Platform, Enters License Agreement for Novimmune Bi-specific Antibody Shire plc,
Published by
GlobeNewswire
18 Jul 17 Shire plc : Notice of Results Shire plc,
Published by
GlobeNewswire
22 Jun 17 Shire Announces EMA Validation of Veyvondi[TM] [Von Willebrand Factor (Recombinant)] Marketing Authorization Application for Treatment of Von Willebrand Disease Shire plc,
Published by
PR Newswire
23 Jun 17 SHIRE TO PRESENT NEW DATA AT ISTH 2017 TO ADVANCE THE STANDARD OF CARE IN HEMOPHILIA Shire Pharmaceuticals Group,
Published by
GlobeNewswire
03 Jul 17 Shire plc : Total voting rights Shire plc,
Published by
GlobeNewswire
06 Jul 17 Shire plc : Additional Listing Shire plc,
Published by
GlobeNewswire
26 Jul 17 Gap In Perceived and Actual Rates Of Prescription Stimulant Misuse, Abuse and Diversion Found Among College Students Shire plc,
Published by
GlobeNewswire
26 Jun 17 Shire to present new data at ISTH 2017 to advance the standard of care in Hemophilia Shire,
Published by
PharmiWeb.com
26 Jun 17 Shire announces EMA validation of VEYVONDI™ [von Willebrand factor (Recombinant)] Marketing Authorization Application for treatment of von Willebrand disease Shire,
Published by
PharmiWeb.com
26 Jun 17 Shire Announces EMA Validation of Veyvondi[TM] [Von Willebrand Factor (Recombinant)] Marketing Authorization Application for Treatment of Von Willebrand Disease Shire ,
Published by
PharmiWeb.com
26 Jun 17 Director Declaration Shire,
Published by
PharmiWeb.com
06 Jul 17 Shire submits investigational New Drug Application to FDA for Gene Therapy candidate SHP654 for treatment of Hemophilia A Shire plc,
Published by
GlobeNewswire
Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.